Mesoblast hits recruitment target in Phase 3 chronic low back pain trial

• Mesoblast hit recruitment target in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease.
• Top-line results have not been presented yet; readout is expected in mid-CY2027.
• Study is designed to confirm earlier findings that rexlemestrocel-L reduced pain and supported lower opioid use.
• Positive results are intended to support an FDA filing in Q3 CY2027, with RMAT status positioning program for priority review once BLA is filed.
• Mesoblast framed indication as major commercial opportunity, citing potential peak-year revenue above USD 10 billion with single-digit market penetration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604282053PRIMZONEFULLFEED9709142) on April 29, 2026, and is solely responsible for the information contained therein.